
Coordinating Multidisciplinary Care in TK2D: Who Leads the Team?
Specialists beyond the mitochondrial physician shape survival through ventilation, cough assist, and pneumonia prevention. A willing, communicative coordinator matters more than the coordinator's specialty.
Episodes in this series

"Coordinating Multidisciplinary Care in TK2D: Who Leads the Team?" takes up the question of how to turn many specialists into one coordinated team.
Dr. Hirano asks how to approach multidisciplinary care after diagnosis and who should always be on the team. Dr. Zolkipli-Cunningham says this influences disease trajectory. In adult cases, responsibility often falls on the diagnosing physician, and the patient may need care in an adult hospital, so she reaches out to adult specialists. The neurologist, neuromuscular doctor, geneticist, and mitochondrial expert lead disease-specific care, dedicated treatment, counseling, and tracking.
Those physicians cannot, however, measure lung function, interpret sleep studies, or manage ventilatory support. She therefore refers patients to adult pulmonologists, and explains to patients who ask why they need another doctor that these specialists bring distinct expertise. Ventilation, pneumonia avoidance, and cough assist machines come from pulmonology and affect survival, not only quality of life. She also brings in cardiology, therapists, a dietitian, gastroenterology, social work, and specialty pharmacy. Communication is essential, and she may receive a report every two or three months on what happened at a pulmonology visit. In her practice, a dozen people may be on one email asking the group to get together for a patient. She calls it a large village.
Dr. Hirano asks who plays the quarterback role. Dr. Zolkipli-Cunningham says it depends on the patient. Primary care or complex care physicians may lead, and she has even met dermatologists who volunteered. Coordinators need not have mitochondrial expertise, but they must be willing to learn and communicate. Dr. Hirano adds that they must read about the disease globally. She suggests inviting collaborators to CME and education days, since TK2D has advanced greatly since approval.
Up next, in "TK2D Treatment Beyond Age 12: Expanded Access and Shared Decision-Making," the panel returns to the 34-year-old patient to discuss therapy options and eligibility.
Related to this article








